Characterization of a Par j 1/Par j 2 mutant hybrid with reduced allergenicity for immunotherapy of Parietaria allergy

Clinical and Experimental Allergy

Volumn 42, Issue 3, 2012, Pages 471-480

  Bonura, A ^a   Passantino, R ^a   Costa, M A ^a   Montana, G ^a   Melis, M ^a   Luisa Bondi M ^b   Butteroni, C ^c   Barletta, B ^c   Corinti, S ^c   Di Felice, G ^c   Colombo, P ^a  

^a Istituto di Biomedicina ed Immunologia Molecolare   (Italy)

^b CNR   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CD3 ANTIGEN; IMMUNOGLOBULIN E; PAR J 1 PROTEIN; PAR J 2 PROTEIN; PJEDLOOP1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VEGETABLE PROTEIN;

ALLERGENICITY; ALLERGY; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOPHIL; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ENGINEERING; HUMAN; HYBRID; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARIETARIA; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIZATION; VACCINATION; WESTERN BLOTTING; WILD TYPE;

ALLERGENS; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC ENGINEERING; HUMANS; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; PARIETARIA; PLANT PROTEINS; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 84857303073     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03938.x     Document Type: Article

References (30)

1. Brunetto B, Tinghino R, Braschi MC, Antonicelli L, Pini C, Iacovacci P. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 2010; 65: 184-90.
2. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008; 38:1400-8.
3. Focke M, Marth K, Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest 2009; 39:429-36.
4. Behrendt H, Kasche A, Ebner von Eschenbach C, Risse U, Huss-Marp J, Ring J. Secretion of proinflammatory eicosanoid-like substances precedes allergen release from pollen grains in the initiation of allergic sensitization. Int Arch Allergy Immunol 2001; 124:121-5.
5. Traidl-Hoffmann C, Mariani V, Hochrein H et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005; 201:627-36.
6. Mariani V, Gilles S, Jakob T et al. Immunomodulatory mediators from pollen enhance the migratory capacity of dendritic cells and license them for Th2 attraction. J Immunol 2007; 178:7623-31.
7. Cortes L, Carvalho AL, Todo-Bom A, Faro C, Pires E, Verissimo P. Purification of a novel aminopeptidase from the pollen of Parietaria judaica that alters epithelial integrity and degrades neuropeptides. The Journal of allergy and clinical immunology 2006; 118:878-84.
8. Taverna S, Flugy A, Colomba P, Barranca M, De Leo G, Alessandro R. Effects of Parietaria judaica pollen extract on human microvascular endothelial cells. Biochem Biophys Res Commun 2008; 372:644-9.
9. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608-13.
10. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:951-60.
11. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101(Suppl 2):14677-82.
12. Purohit A, Niederberger V, Kronqvist M et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38:1514-25.
13. Colombo P, Bonura A, Costa M et al. The allergens of Parietaria. Int Arch Allergy Immunol 2003; 130:173-9.
14. Bonura A, Gulino L, Trapani A et al. Isolation, expression and immunological characterization of a calcium-binding protein from Parietaria pollen. Mol Immunol 2008; 45:2465-73.
15. D'Amato G. Urban air pollution and plant-derived respiratory allergy. Clin Exp Allergy 2000; 30:628-36.
16. D'Amato G, Cecchi L, Bonini S et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007; 62:976-90.
17. Costa MA, Colombo P, Izzo V et al. cDNA cloning, expression and primary structure of Par jI, a major allergen of Parietaria judaica pollen. FEBS Lett 1994; 341:182-6.
18. -Duro G, Colombo P, Costa MA et al. cDNA cloning, sequence analysis and allergological characterization of Par j 2.0101, a new major allergen of the Parietaria judaica pollen. FEBS Lett 1996; 399:295-8.
19. Stumvoll S, Westritschnig K, Lidholm J et al. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 2003; 111:974-9.
20. Bonura A, Corinti S, Artale A et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol 2007; 142:274-84.
21. Bonura A, Artale A, Marino M et al. Cross-reactivity between Parietaria species using the major rParj1 and rParj2 allergens. Allergy Asthma Proc 2006; 27:378-82.
22. Colombo P, Kennedy D, Ramsdale T et al. Identification of an immunodominant IgE epitope of the Parietaria judaica major allergen. J Immunol 1998; 160:2780-5.
23. Bonura A, Amoroso S, Locorotondo G et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 2001; 126:32-40.
24. Pace E, Duro G, La Grutta S et al. Hypoallergenic fragment of Par j 2 increases functional expression of Toll-like receptors in atopic children. Allergy 2006; 61:1459-66.
25. Orlandi A, Grasso F, Corinti S et al. The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin Exp Allergy 2004; 34:470-7.
26. Campana R, Vrtala S, Maderegger B et al. Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol; 2011; 48: 431-41.
27. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-71.
28. Valenta R, Ferreira F, Focke-Tejkl M et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-41.
29. Garcia-Casado G, Pacios LF, Diaz-Perales A et al. Identification of IgE-binding epitopes of the major peach allergen Pru p 3. J Allergy Clin Immunol 2003; 112:599-605.
30. Pacios LF, Tordesillas L, Cuesta-Herranz J et al. Mimotope mapping as a complementary strategy to define allergen IgE-epitopes: peach Pru p 3 allergen as a model. Mol Immunol 2008; 45:2269-76.